Tumor expression of immune checkpoint molecules like PD1, PD-L1 (which binds to PD-1), and CTLA4 (a T-cell immune suppressant that counteracts the stimulatory activity of CD28) are biomarkers of interest to correlate with response to ICI. This evidence concerns the gene CTLA4 and neoplasm.